Replimune Group (NASDAQ:REPL) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Replimune Group (NASDAQ:REPL) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other analysts have also recently weighed in on REPL. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. Finally, Leerink Partners upped their target price on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Replimune Group Stock Up 1.3%

REPL opened at $17.61 on Friday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $18.27. The stock has a market cap of $1.67 billion, a P/E ratio of -6.31 and a beta of 0.93. The stock’s 50 day moving average price is $13.58 and its 200 day moving average price is $9.35. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 5.23.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. As a group, research analysts predict that Replimune Group will post -2.61 earnings per share for the current year.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Hill sold 9,256 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This represents a 4.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares in the company, valued at $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 over the last ninety days. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Replimune Group in the third quarter worth $64,000. Allworth Financial LP bought a new position in Replimune Group in the 2nd quarter worth approximately $62,000. Essential Partners LLC boosted its holdings in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $85,000. Finally, WINTON GROUP Ltd acquired a new stake in Replimune Group during the 2nd quarter worth $115,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.